S Jung1, J Sehouli2, R Chekerov2, F Kluschke3, A Patzelt3, H Fuss4, F Knorr3, J Lademann3. 1. Department of Dermatology, Venerology and Allergology, Center of Experimental and Applied Cutaneous Physiology, Charité - Universitätsmedizin Berlin, Berlin, Germany. sora.jung@charite.de. 2. Department of Gynaecology and Obstetrics, Charité - Universitätsmedizin Berlin, Berlin, Germany. 3. Department of Dermatology, Venerology and Allergology, Center of Experimental and Applied Cutaneous Physiology, Charité - Universitätsmedizin Berlin, Berlin, Germany. 4. Department of Hematology, Oncology and Palliative Care, Helios Klinikum Bad Saarow, Bad Saarow, Germany.
Abstract
PURPOSE:Palmoplantar erythrodysesthesia (PPE) is one of the most frequent side effects during systemic treatment with pegylated liposomal doxorubicin (PLD, Caelyx®). PPE lesions show a range of symptoms, from numbness to painful erosions, and can have a major impact on the quality of life in affected patients. Previously, a possible pathomechanism of PPE was found in doxorubicin-treated patients based on radical formation in the skin. Here, a preventive strategy using a topically applied ointment with a high radical protection factor was investigated. METHODS: In this randomized placebo-controlled double-blind study the antioxidant-containing ointment was compared with a placebo ointment regarding PPE grade III occurrence, overall PPE grade I-III occurrence and PPE severity in PLD patients. The verum or placebo cream was topically applied for a period of 16 weeks, starting 3 days prior to the first cycle of chemotherapy. Clinical evaluations were carried out by a dermatologist prior to the first cycle of chemotherapy and every 4 weeks for the duration of 16 weeks. RESULTS:Thirty-two patients were enrolled in total, of which 17 (66%) completed the study. No PPE grade III was found in the verum group, while five out of seven patients (71%) had to be unblinded in the placebo arm due to PPE grade III (p = 0.003). General PPE occurrence of all grades was 60% under verum and 86% under placebo treatment. CONCLUSIONS: The preventive application of an antioxidant-containing ointment was shown to be significantly more effective in the prevention of PPE grade III compared to placebo treatment.
RCT Entities:
PURPOSE:Palmoplantar erythrodysesthesia (PPE) is one of the most frequent side effects during systemic treatment with pegylated liposomal doxorubicin (PLD, Caelyx®). PPE lesions show a range of symptoms, from numbness to painful erosions, and can have a major impact on the quality of life in affected patients. Previously, a possible pathomechanism of PPE was found in doxorubicin-treated patients based on radical formation in the skin. Here, a preventive strategy using a topically applied ointment with a high radical protection factor was investigated. METHODS: In this randomized placebo-controlled double-blind study the antioxidant-containing ointment was compared with a placebo ointment regarding PPE grade III occurrence, overall PPE grade I-III occurrence and PPE severity in PLD patients. The verum or placebo cream was topically applied for a period of 16 weeks, starting 3 days prior to the first cycle of chemotherapy. Clinical evaluations were carried out by a dermatologist prior to the first cycle of chemotherapy and every 4 weeks for the duration of 16 weeks. RESULTS: Thirty-two patients were enrolled in total, of which 17 (66%) completed the study. No PPE grade III was found in the verum group, while five out of seven patients (71%) had to be unblinded in the placebo arm due to PPE grade III (p = 0.003). General PPE occurrence of all grades was 60% under verum and 86% under placebo treatment. CONCLUSIONS: The preventive application of an antioxidant-containing ointment was shown to be significantly more effective in the prevention of PPE grade III compared to placebo treatment.
Authors: U Jacobi; E Waibler; P Schulze; J Sehouli; G Oskay-Ozcelik; T Schmook; W Sterry; J Lademann Journal: Ann Oncol Date: 2005-04-27 Impact factor: 32.976
Authors: Lígia Traldi Macedo; Joao Paulo Nogueira Lima; Lucas Vieira dos Santos; Andre Deeke Sasse Journal: Support Care Cancer Date: 2014-01-26 Impact factor: 3.603
Authors: Jade Cury-Martins; Adriana Pessoa Mendes Eris; Cristina Martinez Zugaib Abdalla; Giselle de Barros Silva; Veronica Paula Torel de Moura; Jose Antonio Sanches Journal: An Bras Dermatol Date: 2020-02-15 Impact factor: 1.896
Authors: Maxim E Darvin; Jürgen Lademann; Jörg von Hagen; Silke B Lohan; Harald Kolmar; Martina C Meinke; Sora Jung Journal: Antioxidants (Basel) Date: 2022-07-26
Authors: Patricia Palomo-López; David Rodríguez-Sanz; Ricardo Becerro-de-Bengoa-Vallejo; Marta Elena Losa-Iglesias; Jorge Guerrero-Martín; Cesar Calvo-Lobo; Daniel López-López Journal: Cancer Manag Res Date: 2017-11-01 Impact factor: 3.989